Announcements Trials
Browse Landscape

Status

No longer available 2Approved for marketing 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 40Observational 25Expanded_access 3

Sponsor

Cancer Type

Endocrine 3CNS 3Head & Neck 1

Conditions

Prostatic Neoplasms 16Neoplasms 11Neuroblastoma 9Lambert-Eaton Myasthenic Syndrome 7Recurrence 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Multiple Myeloma 6Leukemia 6Carcinoma, Hepatocellular 6Pheochromocytoma 5Lymphoma 5Leukemia, Myeloid, Acute 5Osteosarcoma 4Neuroendocrine Tumors 4Myelodysplastic Syndromes 4Liver Neoplasms 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Glioblastoma 4Sarcoma 3Precancerous Conditions 3Paraganglioma 3Pancreatic Neoplasms 3Neuroectodermal Tumors, Primitive 3Insulinoma 3Immunologic Deficiency Syndromes 3Hematologic Neoplasms 3Glioma 3Carcinoid Tumor 3Breast Neoplasms 3Sarcoma, Ewing 2

Interventions

3-Iodobenzylguanidine 2fluorodopa F 18 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Expanded_access × Paraganglioma × Clear all
NCT01838187 2023-08-18

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Children's Hospital Medical Center, Cincinnati

No longer available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT02431715 2023-02-21

18F-FDOPA PET in Neuroendocrine Tumours

British Columbia Cancer Agency

No longer available
CNSEndocrineHead & Neck

Thyroid cancer, medullary, Carcinoid Tumor, Insulinoma, Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT01377532 2020-05-06

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

University of California, San Francisco

Approved for marketing
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡